UNSPSC 51341806: Sofosbuvir

Antiviral for the treatment of Hepatitis C virus infections

UNSPSC 51341806 Sofosbuvir is a Commodity code nominally representing a single antiviral pharmaceutical product, but recent state and local solicitations tagged with this code do not actually procure sofosbuvir. Instead, the code shows activity for broader pharmaceutical and medical supply procurement — including naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products, and exploratory market research on direct-to-manufacturer prescription programs. The actual work being solicited under this code reflects state health departments, county health authorities, and municipal fire departments acquiring emergency medical supplies, pharmacy benefit program products, and opioid-reversal medications through competitive sealed bidding, RFPs, and market research RFIs. This mismatch between the code's nominal scope and the work actually tagged to it suggests the code is either misapplied in these recent opportunities or serves as a catch-all for pharmaceutical procurement at the state and local level.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2026 deadline. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The City of Tampa issued ITB 26-P-00145 in March 2026 for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, with an estimated contract value of $700,000.00 and a sheltered Small Local Business Enterprise set-aside including a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, with responses due March 26, 2026 and awards effective July 1, 2026. The code shows little relevant recent activity under its stated pharmaceutical scope.